SI

Shoulder Innovations is a commercial-stage medtech executing well on a focused thesis: it does one thing — shoulder arthroplasty implants — and does it profitably at the gross line. FY2025 revenue grew 49.6% to $47.3M with a 76.5% gross margin, and the operating metric management flags in the 10-K corroborates real demand, not channel stuffing: implant systems sold climbed every quarter from 971 in Q1'24 to 1,976 in Q4'25, a clean acceleration. The MD&A's structural tailwind is credible — the shift of shoulder procedures to lower-cost ambulatory surgery centers (ASCs), where the company says it holds a competitive edge, is a genuine secular driver as hospitals face capacity constraints. Outsourced manufacturing keeps the model capital-light, which is why gross margins are this high for a company this small.

The balance sheet is the standout strength and clearly reflects a recent capital raise: total assets rose 294% and equity 357% year-over-year, leaving $141M of equity against just $29.2M of liabilities (0.21x), and $157M of current assets versus $14.2M of current liabilities. Even though headline cash is only $26.9M, the current-asset base implies IPO proceeds parked in short-term investments, giving the company multiple years of runway against its cash burn. Long-term debt is a trivial $14.9M. This is not a company at solvency risk.